Form 4 for GILD Gilead Sciences
Accepted 2024-02-29 00:00:00 ET · period of report 2024-02-28 · accession 0001127602-24-007678 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| M | 2024-02-29 | 2024-02-28+ | GILD | Parsey Merdad | Chief Medical Off | S - Sale | $72.83 | -10.2K | 92.7K | -10% | -$745.0K |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2024-02-28 | S | D | 2,000 | $73.18 | 100,936 | D | — | — | |
| 2 | Common | Common Stock | 2024-02-29 | S | D | 8,230 | $72.74 | 92,706 | D | — | — | (F2) Sale prices reported for the transactions reported here range from $72.454 to $72.88. Full information regarding the number of shares purchased or sold at each separate price will be provided to the SEC, the issuer or its shareowners upon request. (F3) Balance adjusted to reflect shares acquired under the Gilead Sciences, Inc. Employee Stock Purchase Plan. |